Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
5.75
+0.46 (8.70%)
Aug 13, 2025, 1:48 PM - Market open
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
17.40M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
Dec 31, 2021 | 449.00K | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CLDI News
- 4 days ago - Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewsWire
- 18 days ago - Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 - GlobeNewsWire
- 22 days ago - Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 - GlobeNewsWire
- 4 weeks ago - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment - GlobeNewsWire
- 6 weeks ago - Calidi Biotherapeutics Announces Shareholder Letter from CEO - GlobeNewsWire
- 3 months ago - Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - GlobeNewsWire